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Abstract
Advanced tumors produce an excessive amount of transforming growth factor b (TGFb), which promotes
tumor progression at late stages of malignancy. The purpose of this study was to develop anti-TGFb
therapeutics for cancer. We synthesized a novel small-molecule TGFb receptor I kinase (activin receptor–
like kinase 5) inhibitor termedN-[[4-([1,2,4]triazolo[1,5-a]pyridin-6-yl)-5-(6-methylpyridin-2-yl)-1H-imidazol-
2-yl]methyl]-2-fluoroaniline (EW-7197), and we investigated its potential antimetastatic efficacy in mouse
mammary tumor virus (MMTV)/c-Neu mice and 4T1 orthotopic–grafted mice. EW-7197 inhibited Smad/
TGFb signaling, cell migration, invasion, and lung metastasis in MMTV/c-Neu mice and 4T1 orthotopic–
grafted mice. EW-7197 also inhibited the epithelial-to-mesenchymal transition (EMT) in both TGFb-treated
breast cancer cells and 4T1 orthotopic–grafted mice. Furthermore, EW-7197 enhanced cytotoxic T lymphocyte
activity in 4T1 orthotopic–grafted mice and increased the survival time of 4T1-Luc and 4T1 breast tumor–
bearing mice. In summary, EW-7197 showed potent in vivo antimetastatic activity, indicating its potential for
use as an anticancer therapy. Mol Cancer Ther; 13(7); 1704–16. 2014 AACR.
Introduction
Transforming growth factor b (TGFb) is a multifunc-
tional cytokine that plays a central role in a variety of
cellular processes, including cell growth, differentiation,
cell adhesion, migration, and extracellular matrix depo-
sition (1). The binding of TGFb to a heteromeric complex
containing the TGFb receptor facilitates activation of acti-
vin receptor–like kinase 5 (ALK5), which phosphorylates
Smad2/3 (2). Phosphorylated Smad2/3 then forms a
heteromeric complex with Smad4 and is translocated into
the nucleus (3), resulting in altered gene expression (4, 5).
One of the main functions of TGFb signaling is preserva-
tion of the homeostasis of epithelial, endothelial, and
hematopoietic cells. However, in pathologic circum-
stances, the homeostatic action of TGFb is diverted to
alternative roles. During cancer progression, TGFb sig-
naling plays a dual role. At the early stages of tumori-
genesis, TGFb signaling elicits a preventive or tumor-
suppressing effect, and epithelial cells retain delicate
growth sensitivity to TGFb. However, at later stages,
when carcinoma cells become resistant to TGFb-mediated
growth inhibition, the intracellular signaling circuitry of
cells is altered and leads to the progression of tumors (6).
TGFb ligands are often enriched in the breast tumor
microenvironment and can be produced by tumor cells
or tumor-associated stromal and immune cells (4, 7). In
addition, TGFb has been shown to play a critical role in
breast cancer metastasis to the lung and in the mainte-
nance of cancer stem cells (CSC) in breast carcinomas (8–
11). TGFb is also a potent inducer of the epithelial-to-
mesenchymal transition (EMT) in mammary cells (12),
and this transformation has been associated with the
acquisition of tumor stem-like properties (13). Indeed, the
TGFb receptor I/II kinase inhibitor has been shown to
reverse EMT and induce the mesenchymal-to-epithelial
transition in CD44þmammary epithelial cells (7). Studies
with triple-negative breast cancer cells further suggest
that CSCs with self-renewing and tumor-initiating capac-
ities are responsible for chemotherapy resistance and
relapse after treatment (14). Therefore, inhibition of the
TGFb signaling pathway offers a rational approach to
cancer therapy. Thus far, the following three approaches
have been used to inhibit TGFb signaling: (i) inhibition of
TGFb signaling at a translational level using antisense
oligonucleotides (15, 16); (ii) inhibition of the ligand–
receptor interaction using monoclonal antibodies (mAb;
refs. 17–20); and (iii) inhibition of the receptor-mediated
signaling cascade using inhibitors of TGFb receptor
kinases (21). Small-molecule inhibitors of TGFb/ALK5
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kinase activity, such as SD-208 (22), SB-431542 (23),
Ki26894 (24), LY-215799 (14), and LY-2109761 (25), which
compete for the ATP-binding site of ALK5, have been
successfully used to suppress tumor development and
metastasis in animal models. In particular, LY-2157299 is
currently under investigation in a clinical study of
patients with metastatic malignancies to assess the ability
of TGFb inhibitors to block the expansion of chemother-
apy-resistant tumor-initiating cells (14). Nonetheless, no
anti-TGFb therapy is currently available for patients with
metastatic cancer. To develop anti-TGFb therapeutics, we
synthesized a novel small-molecule ALK5 inhibitor, EW-
7197, and investigated its potential usefulness in anti-
TGFb therapy (26). We found that EW-7197 inhibited
Smad/TGFb signaling, cell migration, invasion, and lung
metastasis in mouse mammary tumor virus (MMTV)/c-
Neu and 4T1 orthotopic–grafted mice. EW-7197 also
increased the survival of mice bearing 4T1 breast cancer
tumors. These results demonstrate that EW-7197 repre-
sents a much more potent in vivo TGFb inhibitor than
those previously reported, thus providing a basis for
future clinical studies.
Materials and Methods
Cell lines and culture
4T1 cells and MDA-MB-231 cells were obtained from
Prof. Jeong-Seok Nam (Gachon University of Medicine
and Science, Incheon, Korea) in January 2009. NMuMG
cells and MCF10A cells were obtained from the ATCC in
October 2008. No authentication of these cell lines was
performed by the authors, with the exception of perform-
ing amycoplasma test using the e-Myco plusMycoplasma
PCR Detection Kit (iNtRON BIOTECHNOLOGY) once
per year. All cells were maintained in media containing
penicillin (100 U/mL) and streptomycin (100 mg/mL;
GenDEPOT) at 37C in a humidified incubator in the
presence of 5% CO2. MDA-MB-231, 4T1, and NMuMG
cells were grown in DMEM (GenDEPOT) containing 10%
HI-FBS. Insulin (10 mg/mL; Sigma-Aldrich) was added to
theNMuMGcell cultures.MCF10A cellsweremaintained
in DMEM-F12 (1:1; Gibco) supplemented with 5% horse
serum (Invitrogen), insulin (10 mg/mL), hydrocortisone
(0.5 mg/mL), epidermal growth factor (20 ng/mL), and
cholera toxin (100 ng/mL; Sigma-Aldrich).
Plasmids
The reporter construct, p3TP–Lux, which contains
TGFb-responsive elements, has been described previous-
ly (27). For p3TP–Lux (neo) plasmid construction, the
expression cassette of the neomycin resistance gene (con-
taining SV40 promoter and poly-A sequence) was ampli-
fied from the pGL4.17[luc2/Neo] vector (Promega) by
PCR using i-MAXTM II DNA polymerase (iNtRON Bio-
technology). The neomycin resistance gene was sub-
cloned into the SalI site of the p3TP–Lux plasmid. For
pGL4(CMV)–Luc (neo) plasmid construction, the expres-
sion cassette of the CMV promoter gene was amplified by
PCR as described above and subcloned into the Sal I and
Bgl II sites of pGL4.17[luc2/Neo]. The CMV promoter
primer sequences were as follows: CMV-forward-Sac I
(GAG CTC), 50-C ACT GAG CTC TTA CGG GGT CAT
TAG TTC-30; and CMV-reverse-Bgl II (AGATCT), 50-GCT
TGA GCT CGA GAT CTG AGT CCG GTA G-30.
Generation of 4T1 (3TP-Lux) and 4T1 (CMV-Lux)
stable cells
To generate 4T1-luc [3TP-Lux (neo) and CMV-Luc
(neo)] stable cells, cells were seeded at 1  105 cells
per well in a 6-well plate. After overnight incubation,
cellswere transfectedwith thep3TP–Lux (neo) expression
plasmid using the polyethyleneimine reagent (Sigma-
Aldrich) according to the manufacturer’s instructions,
and the cells were allowed to grow in nonselective medi-
um. Transfected cells were cultured for 4 weeks in medi-
um containing G418 (500 mg/mL; LPS SOLUTION). Sev-
eral single clones of 4T1-luc [3TP-Lux (neo)] cells were
isolated and tested for luciferase expression and respon-
siveness to TGFb1 treatment, and several single clones of
4T1-luc [CMV-Luc (neo)] cellswere isolated and tested for
luciferase activity. The clone showing the highest lucifer-
ase induction was used for the luciferase reporter gene
assay [4T1-luc (3TP-Lux (neo))] and in vivo metastatic
mouse models [4T1-luc (CMV-Luc (neo))].
Animals
BALB/c mice were purchased from Orient Bio Inc. and
maintained in a temperature-controlled room (at 21C)
and supplied with food andwater. MMTV/c-Neu female
mice were maintained in a temperature-controlled–spe-
cific pathogen-free room (22C) and supplied with auto-
claved food and water. After the animals were sacrificed,
blood and tissues were collected. Tissues were sliced into
sections, snap-frozen in liquid nitrogen, and stored at
70C. All experimental procedures were conducted in
accordance with our institutional guidelines.
Breast cancer model #1 using MMTV/c-Neu mice
When the total mammary tumor volume was 100 mm3,
32-week-old MMTV/c-Neu mice were randomized and
treated (i.p.) with saline (Veh; n ¼ 7) or EW-7197HCl
dissolved in saline (43.7mg/kg; equivalent to 40mg/kgof
EW-7197, n ¼ 10) three times per week for 10 weeks.
Breast cancer models #2, #3, and #4 using 4T1
orthotopic–grafted mice
In efficacy experiments (models #2 and#3), 1.2 104 4T1
cells were suspended in saline and implanted into the left
mammary fat pads (#4) of female BALB/c mice (50 mL/
mouse; day 0). Tumor size and body weight were mea-
sured weekly. Artificial gastric fluid (Veh), EW-7197 (5 or
20 mg/kg), or LY2157299 (40 or 80 mg/kg) dissolved in
Veh was administered orally to mice five times per week
starting fromday 4 for a total of 28 days (model #2; n¼ 10/
group). Veh or EW-7197 (5, 10, 20, or 40 mg/kg) was
administered tomice three timesperweek fromday4 for a
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total of 28 days (model #3; n¼ 68/group). For the TGFb1
challenge experiment in the model #3, 2 mice from each
group were selected and treated with the indicated con-
centration of EW-7197 on day 28. After 30 minutes, 1
animal per group was injected (i.v.) with TGFb1 (50
ng/mouse), and the other animal was left untreated. At
90minutes after TGFb1 injection, themicewere sacrificed.
In survival experiments (model #4), 1.6  104 4T1 cells
were injected as in the model #2, and Veh or EW-7197 (2.5
or 5 mg/kg) dissolved in Veh was administered orally
to the mice five times per week from day 7 until death
(n ¼ 11/group).
Thebreast cancermodel#5using the4T1-luc tail vein
mouse model
4T1-luc cells [2  105; transfected with the plasmid
construct pGL4(CMV-Luc)]were suspended in saline and
injected into the tail veins of female BALB/cmice (50 mL/
mouse; day 0). Artificial gastric fluid (Veh) or EW-7197
(0.625, 1.25, 2.5, or 5 mg/kg) dissolved in Vehwas admin-
istered orally to mice five times per week from day 0 until
death (n ¼ 13/group). On day 15, surviving mice were
analyzed using an in vivo imaging system to compare
metastases in the lungs. Luciferase-positive 4T1 cellswere
imaged with the IVIS-200 system (Xenogen Corporation).
The captured images were quantified using the Living
Image Software package (PerkinElmer/Caliper Life
Sciences).
Breast cancer model #6 using 4T1-luc orthotopic–
grafted mice
4T1-luc cells [3  104; transfected with the plasmid
construct pGL4(CMV-Luc)] were implanted into the left
#4 mammary fat pads of female BALB/c mice as in the
model #2 (day 0). Tumor size and body weight were
measured weekly. Artificial gastric fluid (Veh) or EW-
7197 (2.5, 5, 10, or 20 mg/kg) dissolved in Veh was
administered orally to mice five times per week (2.5, 5,
or 10 mg/kg) or three times per week (20 mg/kg) starting
from day 4 for a total of 28 days (n ¼ 15/group).
India ink staining
Mice were sacrificed, and 15% India ink solution (Har-
dy Diagnostics) in PBS was injected into the lung through
the trachea. The number of metastatic nodules on the
surface of the left lobeof the lungwas counted, and images
of the lungs were taken with a digital camera (Nikon).
Western blot analysis
Mouse tissues or cells were homogenized in RIPA
buffer (27). Lysates containing 4 to 50 mg of total protein
were separated by electrophoresis onpolyacrylamide gels
and then transferred electrophoretically to a polyvinyli-
dene difluoride transfermembrane (Millipore). Themem-
brane was blocked with 5% bovine serum albumin (Sig-
ma-Aldrich) and incubated overnight at 4C with the
indicated primary antibodies (Supplementary Table S1).
The membrane was then incubated with horseradish
peroxidase–conjugated secondary antibodies. Bound
antibodieswere detectedwith theWestern Blotting Lumi-
nol Reagent (Santa Cruz Biotechnology).
Wound-healing assay
4T1 cells andMDA-MB-231 cells were seeded in 6-well
plates. When more than 80% of the area of each well was
occupied by cells, 10% HI-FBS medium was changed to
0.2% HI-FBS medium. After 24 hours, a "wound" was
made by scrapingwith a plastic pipette tip (time¼ 0), and
the cells were treated with TGFb1 (2 ng/mL) with or
without ALK5 inhibitors for 24 hours (4T1) or 53 hours
(MDA-MB-231). The wound area at zero time or the end
point was measured using the ImageJ program according
to phase-contrast images of the cells captured with a
camera attached to a microscope (Carl Zeiss). The closure
of the wound area was calculated as a percentage of the
initial wound area.
Matrigel invasion assay
The upper surface of a Transwell (6.5-mmdiameter and
8-mmpore size; Corning) was coatedwith 20 mL of diluted
33.3%Matrigel (BD Biosciences). 4T1 cells were seeded at
4  104 cells per well in the upper chamber of the Trans-
well in serum-freemediumwith or without TGFb1 (2 ng/
mL) in the presence or absence of ALK5 inhibitors. The
lower chamber was filled with the samemedium as in the
upper chamber but with 10%HI-FBS. After incubation for
20 hours, the cells remaining on the upper surface of
the membrane were removed with a cotton swab, and
the DAPI-stained cells remaining on the bottom surface
were observed using fluorescence microscopy (Carl
Zeiss). The average cell number per field of view was
obtained from five random fields.
Luciferase reporter gene assay
4T1 (3TP-Lux) stable cells (27) were seeded into a 96-
well plate at 2.5  104 cells per well and treated with
TGFb1 (2 ng/mL) and ALK5 inhibitors in 0.2% HI-FBS
medium for 24 hours. Luminescencewasmeasured in cell
lysates with a luminometer (Micro Lumat Plus; Berthold
Technologies). Detailed information is described in the
Supplementary Materials and Methods.
Immunofluorescence assay
Cells were fixed with 4% formaldehyde and incubated
with an anti-Smad2/3 antibody (BD Biosciences) or an
anti–E-cadherin antibody (Cell Signaling Technology) at
4C overnight. Target proteins were visualized by the
addition of Cy3-conjugated goat anti-mouse IgG or Alexa
Fluor 488–conjugated anti-rabbit IgG (Cell Signaling
Technology). Nuclei were counterstained with DAPI.
Fluorescence was visualized using the LSM 510 META
laser confocal microscopy system (Carl Zeiss). To visual-
ize the infiltration of CD8þ cells into the primary tumors,
slides of paraffin-embedded primary tumors were incu-
bated with PE-conjugated anti-CD8a (BD Biosciences) at
4C overnight. Images were captured as described above.
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Figure 1. EW-7197 inhibits TGFb1/Smad signaling. A, chemical structure of EW-7197. B, effects of EW-7197 on 3TP-Lux promoter activity induced by TGFb1.
Themeanof luciferase activity is expressed as a percentage of the luciferase activity in the control (n¼3). Data,meanSD. The nonlinear regression (curve ﬁt)
equation was calculated using GraphPad prism. C, blockade of Smad3 phosphorylation by ALK5 inhibitors. 4T1 cells were treated with the indicated
chemicals for 30 minutes with or without TGFb1. D, blockade of Smad2/3 nuclear translocation by EW-7197. 4T1 cells and MCF10A cells were treated with
EW-7197 for 2 hours with or without TGFb1 and processed as described in Materials and Methods. Representative confocal images are presented (red,
smad2/3; blue, DAPI; total magniﬁcation, 800; scale bar, 20 mm).
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RNA extraction and RT-PCR and qRT-PCR
Total RNA was isolated from mouse tissues and cells
using the TRizol reagent (Invitrogen). cDNAwas synthe-
sized from 2 mg of total RNA using M-MLV reverse
transcriptase (Invitrogen) and random primers (Invitro-
gen), and the cDNA was subjected to PCR amplification
using Taq polymerase (Promega). Amplified DNA was
analyzed by agarose gel electrophoresis. For real-time
quantitative RT-PCR, cDNA was synthesized from RNA
isolated from mouse tissues and cells as described above.
The Power SYBR Green PCR Master Mix and Step-One
Real-time PCR systems (Applied Biosystems) were used
for the PCR amplification of cDNA. The primers used are
listed in Supplementary Table S2.
Protein kinase assay
Selectivity profiling of EW-7197 against 320 protein
kinases was performed at doses of 1  108, 1 107, 1
106, and 1  105 mol/L with a radiometric protein
kinase assay (33ProQinase Activity Assay) provided by
ProQinase (27). Detailed information is described in the
Supplementary Materials and Methods.
Statistical analysis
Data arepresented as themeanSD (in vitro) ormean
SE (in vivo). Statistical values were defined using the
Student t test (between twogroups) or a one-wayANOVA
with the Dunnett multiple comparison test (among more
than two groups); , P < 0.05; , P < 0.01; and , < 0.005,
respectively.
Results
EW-7197 inhibits TGFb/Smad signaling
We synthesized EW-7197, a small-molecule ATP-com-
petitive inhibitor of TGFbRI (ALK5), which binds to the
ATP-binding site in the kinase domain of ALK5 (Fig. 1A).
We compared the activity of EW-7197 with those of other
ALK5kinase inhibitors using a reporter gene assay in 4T1-
3TP-Lux cells. The IC50 values of EW-7197, IN-1130, SB-
505124, and LY-2157299 were 13.2, 45.8, >50, and >100
nmol/L, respectively, in 4T1-3TP-Lux cells (Fig. 1B). We
also performed a radiometric protein kinase assay (33Pan-
QinaseActivityAssay) tomeasure the kinase selectivity of
EW-7197 over the 320 protein kinases in ProQinase (data
not shown). The specificity of EW-7197 for ALK5was 138-
fold greater than that for the p38a protein kinase, which
has one of themost homologous kinase domains to that of
ALK5. The IC50 values of EW-7197 againstALK5 andp38a
were 12.9 and 1775 nmol/L, respectively (Table 1). EW-
7197 also inhibits ACVR1B/ALK4 and the IC50 value
against it was determined to be 17.3 nmol/L (data
not shown). EW-7197 inhibited ALK-2/ACV-R1 at con-
centrations comparable with ALK-5 (Supplementary
Table S3). Because the ATP-binding site of the ALK5
kinase domain is essential for phosphorylation of the
substrates Smad2/3, we evaluated the inhibitory effect
of EW-7197 on Smad2/3 phosphorylation. EW-7197
blocked the TGFb-induced phosphorylation of Smad2 or
Smad3 in a dose-dependent manner in 4T1 cells (Fig. 1C
and Supplementary Fig. S1A), NMuMG (Supplementary
Fig. S1B), and MDA-MB-231 cells (Supplementary Fig.
S1C). EW-7197 suppressed the TGFb-induced nuclear
translocation of Smad2/3 in 4T1 cells and MCF10A cells
(Fig. 1D). The IC50 values of EW-7197, SB-505124, LY-
2157299, and IN-1130onpSmad3 in 4T1 cellswere 10 to 30,
300 to 500, 500 to 1,000, and 300 to 500 nmol/L, respec-
tively (Fig. 1C). EW-7197 showed amore potent inhibitory
effect on TGFb-induced Smad2 or Smad3 phosphoryla-
tion than other ALK5 inhibitors previously identified.
EW-7197 abrogates TGFb1-induced tumor cell
migration and invasion
TGFb1 is known to stimulate the migration of tumor
cells (28). To study the effect of EW-7197 on the cellular
migration and invasion mediated by TGFb1, we per-
formed wound-healing and Matrigel invasion assays.
In the wound-healing assay, we compared the effect of
EW-7197 with that of other ALK5 inhibitors, such as SB-
505124, IN-1130, and LY-2157299, at various concentra-
tions (0.1, 0.5, and 1 mmol/L) in 4T1 cells and MDA-MB-
231 cells. TGFb1 accelerated cell motility and wound
closure, and EW-7197 showed stronger inhibition of
TGFb1-induced cell migration than SB-5050124 or LY-
2157299 (Fig. 2A and B and Supplementary Fig. S2A). In
theMatrigel invasion assay, TGFb1 enhanced the invasion
of 4T1 cells by 3-fold and EW-7197 strongly attenuated
TGFb1-induced cell invasion. However, LY-2157299 did
not inhibit cell invasion at a concentration of 1 mmol/L
(Fig. 2C). We also examined whether the inhibitory effect
Table 1. Kinase inhibition assay against TGFbRI and p38a
IC50 (nmol/L)
Compound ALK5 P38a Selectivity index
EW-7197 12.9 1,775 138
IN-1130 13.0 288 22
SB-505124 26.8 640 24
NOTE: IC50 values of the compound against TGFbRI and p38awere measured using a radiometric protein kinase assay (33ProQinase
Activity Assay; ProQinase), which is described in the Supplementary Materials and Methods.
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Figure 2. Effect of EW-7197 on cell migration and invasion. Wound-healing assays (described in Materials and Methods) using 4T1 cell for 24 hours (A) and
MDA-MB-231 cell for 53 hours (B). Representative phase-contrast images are presented (total magniﬁcation,100; scale bar, 100 mm). Data, mean SD of
the closed wound area shown as a percentage of the initial wound area (n ¼ 4). Statistical signiﬁcance was deﬁned using one-way ANOVA with the
Dunnett multiple comparison test. C, Matrigel invasion assay using 4T1 cells (described in Materials and Methods). Representative ﬂuorescence images are
presented (total magniﬁcation,100; scale bar, 100 mm). Data, mean SD of the number of invaded cells per ﬁeld of view (n¼ 3). Statistical signiﬁcance was
deﬁned as described above; , P < 0.05; , P < 0.01, and , P < 0.005, respectively.
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of EW-7197 on cell migration and invasion was due to the
inhibition of cell proliferation, andwe found that EW-7197
did not affect the proliferation of 4T1 and MCF10A cells
(Supplementary Fig. S2B and S2C), although EW-7197
inhibited 4T1 cell proliferation when added at a high
concentration (5,000 nmol/L). Thus, EW-7197 strongly
suppressed the TGFb1-induced migration and invasion
of breast cancer cells.
EW-7197 inhibits EMT in breast cancer cells
TGFb induces the progression of epithelial cancer and
promotes metastasis via the alteration of cellular plastic-
ity, loss of cell–cell contact, increased cell migration,
increased invasion, and degradation of the extracellular
matrix. The EMT in epithelial cells is characterized by the
acquisition of a spindle morphology and increased
motility with the loss of the tight and adherent junctions
(12, 29, 30). To examine the effect of EW-7197 on TGFb1-
induced EMT, we used mouse mammary epithelial cells
(NMuMG) and immortalized human mammary epithe-
lial cells (MCF10A). TGFb1 treatment changed the mor-
phology of NMuMG cells from a cuboidal shape to an
elongated spindle-like shape and from a dense distribu-
tion to a sparse distribution within 48 hours (Fig. 3A),
which was consistent with previous studies (12). EW-
7197 also inhibited the change inmorphology inducedby
TGFb1 more efficiently than SB-505124 and LY-2157299.
E-Cadherin is known to be one of the cell–cell interaction
proteins that is destroyed during TGFb1-induced EMT.
We confirmed E-cadherin protein expression using an
immunofluorescence assay with confocal microscopy.
EW-7197 inhibited the TGFb1-induced delocalization
and the loss of E-cadherin expression in NMuMG cells
(Fig. 3B). We further confirmed byWestern blot analysis
that TGFb1 reduced the expression of E-cadherin, but
increased that of N-cadherin, Snail, and Fibronectin, and
these changes were reversed by concomitant treatment
with EW-7197 and TGFb1 in MCF10A cells (Fig. 3C). For
a more detailed comparison, we performed experiments
using a broad range of concentrations of other ALK5
inhibitors. EW-7197 inhibited the morphologic change
induced by TGFb1 at a lower concentration than other
ALK5 inhibitors (Supplementary Fig. S3A). At the same
time, EW-7197 restored E-cadherin expression, which
was reduced by TGFb1, whereas it ameliorated N-cad-
herin expression, which was induced by TGFb1, at a
lower concentration than other ALK5 inhibitors (Sup-
plementary Fig. S4A). As TGFb induces EMT through
transcriptional regulation, we examined the effect of
EW-7197 on transcriptional regulators, such as SNAI1,
SNAI2, and HMGA2, as well as markers of EMT, such as
CDH1 and FN.TGFb1 downregulated themRNA level of
CDH1 and upregulated the mRNA levels of FN1,
HMGA2 (high-mobility group AT-hook 2), SNAI1, and
SNAI2 (Snail family zinc finger 1 and 2, respectively).
Moreover, EW-7197 abolished the TGFb1-induced
effects on genes related to EMT (Fig. 3D). The inhibition
of TGFb1-induced EMT by EW-7197 may be mediated
through the regulation of mRNA and protein levels, and
EW-7197 showed potent inhibition of EMT compared
with SB-505124.
EW-7197 inhibits breast cancer metastasis to the
lung
Epidemiologic analysis of a cohort of 615 human breast
tumors has shown that the TGFb signaling pathway may
be linked to breast cancer metastasis to the lung (28). EW-
7197 (40 mg/kg) treatment of MMTV/c-Neu transgenic
mice significantly reduced lung metastasis by 60% com-
pared with the control, based on Csn2 (b-casein) mRNA
levels in the lung tissue (Fig. 4A).We confirmed the tumor
burden in metastasized lungs by hematoxylin and eosin
(H&E) staining (Supplementary Fig. S5A). The total tumor
volume and body weight did not differ between saline-
(Veh) and EW-7197–treated groups (Supplementary Fig.
S5B and S5C). To examine the antimetastatic effect of EW-
7197 on breast cancer metastasis to the lung in vivo, the
BALB/c 4T1 metastatic breast cancer model was estab-
lished. Specifically, 4T1 cells were transplanted into the
mammary fat pads of BALB/c mice (day 0), which were
treatedwith either artificial gastric fluid (Veh), EW-7197 (5
or 20 mg/kg) or LY2157299 (40 or 80 mg/kg) orally five
times per week from day 4 to day 28. Treatment with
EW-7197 and LY2157299 decreased the number of met-
astatic nodules compared with that in the Veh-treated
control group by 53% and 68% (5 and 20 mg/kg) and by
33% and 53% (40 and 80 mg/kg), respectively (Fig. 4B).
EW-7197 showed a more potent inhibitory effect on
the metastasis of breast cancer cells to the lung than
LY2157299. There was no difference in primary tumor
size (Fig. 4C) or body weight (Supplementary Fig. S5D)
between the Veh-treated group and the EW-7197–
or LY2157299-treated group. Because treatment with
5 mg/kg EW-7197 every day for 5 days per week showed
the maximal effect, we performed EW-7197 treatment (5,
10, 20, or 40 mg/kg) every other day (three times/week)
from day 4 to day 28 to examine a possible dose relation-
ship. The results showed that EW-7197 decreased the
number of metastatic nodules in a dose-dependent man-
ner without inducing any effects on the primary tumor
size or body weight (Fig. 4D and E and Supplementary
Fig. S5E), and the efficacy of EW-7197 reached a plateau
after 20 mg/kg. In TGFb1 challenge experiments, EW-
7197 inhibited Smad2 phosphorylation in primary tumors
in a dose-dependent manner (Supplementary Fig. S5F).
EW-7197 prolongs the life span of BALB/c 4T1 mice
via inhibition of EMT
EW-7197 (5 mg/kg five times/week) treatment was
sufficient to produce the maximal antimetastatic effect.
EW-7197 (0.625, 1.25, 2.5, or 5 mg/kg; five times/week)
inhibited lung metastasis and increased the survival of
4T1-Luc cells, which were injected via the tail vein into
BALB/c mice, in a dose-dependent manner (Fig. 5A and
B). On the 22nd day, the percentage of surviving control
mice was 7.7%, whereas the percentage of surviving mice
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Figure 3. Effect of EW-7197 on EMT. A and B, NMuMG cells were treated with TGFb1 (2 ng/mL) with or without ALK5 inhibitors in serum-reduced (5%HI-FBS)
medium for 2 days. A, cell morphology was observed by phase-contrast microscopy (total magniﬁcation, 100; scale bar, 100 mm). B, for visualization of E-
cadherin (green), NMuMGcellswere cultured as described above andprocessed as described inMaterials andMethods. Representative confocal images are
presented (blue, DAPI; total magniﬁcation, 400; scale bar, 20 mm). C and D, MCF10A cells were treated with TGFb1 (2 ng/mL) in 0.2%% HI-FBS medium
with or without ALK5 inhibitors. C, after 96 hours, cell morphology was observed by phase-contrast microscopy (total magniﬁcation, 100; scale bar,
100 mm) and total protein was isolated and analyzed using speciﬁc antibodies against EMT markers (E-cadherin, N-cadherin, SNAIL, and ﬁbronectin) by
Western blotting. b-Actin was used for endogenous reference. D, total RNA was isolated and mRNA transcript levels of CDH1, FN1, HMGA2, SNAI1, and
SNAI2 were analyzed by RT-PCR. Data were normalized against GAPDH. Data, mean  SD (n¼ 3). Statistical signiﬁcance was deﬁned by one-way ANOVA
with the Dunnett multiple comparison test; , P < 0.01 and , P < 0.005, respectively.
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Figure 4. EW-7197 inhibits breast cancer metastasis to the lung. A, EW-7197 inhibited lung metastasis of the breast tumor in vivo breast cancer model #1
(described in Materials and Methods). Inhibition of lung metastasis by EW-7197 (40 mg/kg) in MMTV/c-Neu mice was evaluated by measuring the mRNA
expression of Csn2 (b-casein) in lungs using RT-PCR. Data were normalized against Gapdh. Data, mean  SE (Veh, n ¼ 7; EW, n ¼ 10). Statistical
signiﬁcancewas deﬁnedusing theStudent t test. B andC, the breast cancermodel #2 (described inMaterials andMethods). B, inhibition of lungmetastasis by
EW-7197 was evaluated by India ink staining. Representative images of lungs with metastatic nodules (white spots) are shown (top; scale bar, 1 cm). Data,
number of metastatic nodules as the mean  SE (n ¼ 10/group; bottom). Statistical signiﬁcance was deﬁned using one-way ANOVA with the Dunnett
multiple comparison test. C, effects of EW-7197 on primary tumor volume. D and E, the breast cancer model #3 (described in Materials and Methods).
D, inhibition of lung metastasis by EW-7197 was evaluated by India ink staining. Representative images of lungs (top) and the number of metastatic
nodules (bottom) arepresented asdescribed above (n¼68/group). Statistical valuesweredeﬁnedasabove. E, effectsof EW-7197onprimary tumor volume;
, P < 0.05 and , P < 0.01, respectively.
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Figure 5. EW-7197 prolongs the life span of BALB/c 4T1mice via inhibition of EMT. A and B, the breast cancermodel #5 (described inMaterials andMethods).
A,metastasis to the lungswas visualized by bioluminescence analysis as described inMaterials andMethods. The image (left) shows the region ofmetastatic
area in three representative mice per each group. Data, mean  SE (n ¼ 13/group). B, effect of EW-7197 on survival. Data, the percentage of survival
in each group on the indicated day (n¼ 13/group). Kaplan–Meier curves were produced using GraphPad Prism. Statistical values were deﬁned using the log-
rank test. C, the breast cancer model #4 (described in Materials and Methods). Effect of EW-7197 on survival (n ¼ 11/group). Survival curves and statistical
values were produced as described above. D, the breast cancer model #3 (described in Materials and Methods). Effect of EW-7197 on EMT in primary
tumors.Western blots (top) and quantiﬁcation of all samples fromeachgroup (bottom). Datawere normalized tob-actin. Data,meanSE (n¼5/group) shown
as a percentage of the artiﬁcial gastric ﬂuid (Veh)–treated group. Statistical signiﬁcance was deﬁned using one-way ANOVA with the Dunnett multiple
comparison test; , P < 0.05; , P < 0.01, and , P < 0.005, respectively.
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treated with EW-7917 at 0.625, 1.25, 2.5, and 5 mg/kg was
30.8, 46.1, 61.5, and 69.2%, respectively (Fig. 5B). EW-7197
also prolonged the survival of BALB/c mice orthotopi-
cally bearing 4T1 tumors by 36% at doses of 2.5 and 5mg/
kg (Fig. 5C). These findings suggested that EW-7197
inhibited the lungmetastasis of breast tumor cells, thereby
enhancing the life-span of mice bearing breast tumors. To
further investigate themechanismof the effect of EW-7197
on metastasis, we analyzed the protein levels of EMT
markers in primary tumors by Western blotting. EW-
7197 treatment increased E-cadherin and decreased Snail
expression in a dose-dependent manner (Fig. 5D), and N-
cadherin was also decreased by EW-7197 treatment (Fig.
5D). These results indicated that EW-7197 may inhibit
metastasis to the lung in vivo via the inhibition of EMT,
although this compound did not affect primary tumor
growth.
EW-7197 inhibits metastasis and enhances the
activityof cytotoxicT lymphocytes in4T1orthotopic–
grafted mice
EMT profoundly alters the susceptibility of cancer cells
to T-cell–mediated immune surveillance (30). Therefore,
we next tested whether EW-7197 treatment would affect
immune surveillance. We performed an immunofluores-
cence assay in primary tumors of 4T1 orthotopic–grafted
mice against the CD8 protein, which is expressed on the
surface of cytotoxic T lymphocytes (CTL). The intensity of
the CD8þ area showed that EW-7197 increased the infil-
tration of CD8þ immune cells into primary tumors (Fig.
6A and B). We confirmed these results by measuring the
mRNA level of CD8 (Cd8b1) in primary tumors relative to
that of peptidylprolyl isomerase A (cyclophilin A, Ppia),
an endogenous housekeeping gene, using real-time qPCR
(Fig. 6B). Because the cytolytic activity and number of
Figure 6. EW-7197 inhibits
metastasis and enhances the
activity of CTLs in 4T1 orthotopic–
grafted mice. A to C, the breast
cancer model #6 (described in
Materials and Methods). Effect of
EW-7197 on the inﬁltration of
CD8þ cells in primary breast
tumors. A, the CD8þ cells in
primary tumors were visualized by
immunoﬂuorescence staining
(described in Materials and
Methods). Representative
confocal images are presented
(total magniﬁcation, 400; scale
bar, 25 mm; red, Cd8a; blue, DAPI)
and matched with H&E-stained
images. B, Cd8aþ area (above)
was calculated as the percentage
of the total ﬁeld and presented as
fold to the artiﬁcial gastric ﬂuid
(Veh)–treated group. The mRNA
level of Cd8b1 in primary breast
tumors was analyzed by qRT-PCR
and normalized by Ppia (n ¼ 47/
group). Statistical signiﬁcance was
deﬁned using one-way ANOVA
with the Dunnett multiple
comparison test. C, effect of EW-
7197 on the activity of CTLs.
Cytolytic activity of CTLs was
measured by qRT-PCR analysis of
Prf1 and Gzmb expression
normalized to Cd8b1 in primary
breast tumors. Boxes, median
values with the upper and lower
quartiles, and whiskers, the range
(n ¼ 47/group). Statistical
signiﬁcance was deﬁned as
described above. , P < 0.05.
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CTLs are important, we analyzed the cytolytic effector
functions of CTLs, such as perforin, which forms pores
on the membrane of target cells, and granzyme B, a
catalytic enzyme released from CTLs into the cytosol of
target cells. The cytolytic activity of CTLs was analyzed
by measuring the expression of perforin (Prf1) and
granzyme B (Gzmb) relative to that of CD8. The results
showed that the cytolytic activity of CTLs was increased
following EW-7197 treatment in a dose-dependent man-
ner (Fig. 6C). At the same time, EW-7197 decreased lung
metastasis in a dose-dependent manner without any
effects on primary tumor size (Supplementary Fig. S6).
This finding may suggest that EW-7197 inhibits the
pulmonary metastasis of breast cancer and improves
immune surveillance in terms of CTL activity and
recruitment.
Discussion
TGFb inhibitors are being developed as antimetastatic
agents for treating patients with cancer because TGFb has
a variety of antitumorigenic effects (16–25, 31). Although
ligand traps, such as 1D11 (17), and antisense-specific
oligos (ASO), such as AP12009 (32), limit the bioavailabil-
ity of active TGFb ligands, they fail to directly block
signaling through the receptor.Moreover, small-molecule
inhibitors of TGFb receptor kinases can block receptor
signaling, although such kinase inhibitors demonstrate
lower specificity than ASOs or mAbs. Previous studies
suggest that many small-molecule inhibitors of TGFbRI/
ALK5 also inhibit the related activin and nodal receptors,
namely ACVR1B/ALK4 and ACVR1C/ALK7, but with a
reduced affinity (32, 33). EW-7197 also inhibited TGFbRI/
ALK5 (IC50 ¼ 12.9 nmol/L) and ACVR1B/ALK4 (IC50 ¼
17.3 nmol/L), but the specificity of EW-7197 for ALK5
inhibition was 138-fold greater than that for the p38a
protein kinase (Table 1). Although EW-7197 is designed
to have a great specificity toALK-5,we cannot rule out the
possibility that the inhibition of ALK-2/ACV-R1may also
contribute to someof the phenotypic responses and in vivo
activity observed in the present studies. It has been more
difficult to demonstrate a significant reduction in primary
tumors, although TGFb signaling inhibition results in a
significant reduction in metastasis in mouse models. Sim-
ilarly, EW-7197was found to inhibit the lungmetastasis of
breast tumors in mouse models without affecting the
primary tumor size (Fig. 4). These facts suggest that
combinatorial therapy may enhance the efficacy of TGFb
inhibitors in clinical practice. The TGFbRI/II kinase inhib-
itor, LY-2109761, in combination with temozolomide and
radiotherapy in a glioblastoma model was shown to
inhibit tumor growth compared with controls (25). Fur-
thermore, loss of TGFb signaling can increase the thera-
peutic efficacy of cancer treatment with rapamycin (34)
and doxorubicin (35). In the 4T1 mouse model, a combi-
nation of ixabepilone, capecitabine, and 1D11 treatment
reduces primary tumor growth and metastasis (36), and
this combinatorial treatment has also shown some efficacy
for patients with breast cancer resistant to anthracycline
and taxane therapy (36). Metastatic triple-negative breast
cancers often recur after chemotherapy (37), and meta-
static tumor relapses are characterized by rapid cellular
proliferation due to the survival of a small population of
cells with stem-like properties and drug resistance (8–10).
Thus, itwouldbe interesting to examinewhetherEW-7197
may improve the efficacy of paclitaxel in combinatorial
treatment. The reference suggested that cells that harbor
autocrine TGFb signaling are causally associated with
resistance to paclitaxel (14) and TGFb-induced EMT has
been associated with the acquisition of tumor stem-like
properties (13). The TGFb signaling pathway is involved
in the maintenance of cancer stem cells in breast carcino-
mas (14). Indeed, a TGFbRI/II kinase inhibitorwas shown
to reverse EMT and induce mesenchymal-to-epithelial
differentiation in CD44þ mammary epithelial cells (15).
This study demonstrated that the novel small-molecule
TGFb receptor I kinase ALK5 inhibitor, EW-7197, inhib-
ited Smad/TGFb signaling, EMT, cellmigration, invasion,
and lung metastasis in orthotopic-grafted mice. Further-
more, EW-7197 increased the survival time of mice bear-
ing 4T1-Luc breast tumors.
In summary, EW-7197 could be used as an antimeta-
static drug in oncology. Our data strongly indicate that
our novel small-molecule ALK5 inhibitor, EW-7197,
showed therapeutic antimetastatic effects in 4T1 breast
tumor-bearing mice. However, further clinical studies
and trials are necessary to validate the therapeutic poten-
tial of EW-7197.
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